FI905941A0 - Förfarande för framställning av terapeutiskt användbara heterocykliska 2-acylaminotiazolderivat - Google Patents

Förfarande för framställning av terapeutiskt användbara heterocykliska 2-acylaminotiazolderivat

Info

Publication number: FI905941A0
Authority: FI; Finland
Prior art keywords: preparation; therapeutically useful; useful heterocyclic; acylaminothiazole derivatives; acylaminothiazole
Prior art date: 1989-12-06

Application number

FI905941A

Other languages

English (en)

Finnish (fi)

Other versions

FI905941A7 (sv

FI94249B (sv

FI94249C (sv

Inventor

Jean-Pierre Bras

Daniel Frehel

Danielle Gully

Gerard Valette

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-12-06

Filing date

1990-12-03

Publication date

1990-12-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26227714&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI905941(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1989-12-06 Priority claimed from FR8916122A external-priority patent/FR2655344B1/fr

1990-05-04 Priority claimed from FR9005669A external-priority patent/FR2661677B1/fr

1990-12-03 Application filed by Sanofi Sa filed Critical Sanofi Sa

1990-12-03 Publication of FI905941A0 publication Critical patent/FI905941A0/sv

1991-06-07 Publication of FI905941A7 publication Critical patent/FI905941A7/sv

1995-04-28 Publication of FI94249B publication Critical patent/FI94249B/sv

1995-08-10 Application granted granted Critical

1995-08-10 Publication of FI94249C publication Critical patent/FI94249C/sv

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Child & Adolescent Psychology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Indole Compounds (AREA)

FI905941A 1989-12-06 1990-12-03 Förfarande för framställning av terapeutiskt användbara heterocykliska 2-acylaminotiazolderivat FI94249C (sv)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
FR8916122		1989-12-06
FR8916122A FR2655344B1 (fr)	1989-12-06	1989-12-06	Derives heterocycliques d'acylaminothiazoles, leur preparation et compositions pharmaceutiques en contenant.
FR9005669		1990-05-04
FR9005669A FR2661677B1 (fr)	1990-05-04	1990-05-04	Derives heterocycliques d'acylaminothiazoles, leur preparation et compositions pharmaceutiques en contenant.

Publications (4)

Publication Number	Publication Date
FI905941A0 true FI905941A0 (sv)	1990-12-03
FI905941A7 FI905941A7 (sv)	1991-06-07
FI94249B FI94249B (sv)	1995-04-28
FI94249C FI94249C (sv)	1995-08-10

Family

ID=26227714

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI905941A FI94249C (sv)	1989-12-06	1990-12-03	Förfarande för framställning av terapeutiskt användbara heterocykliska 2-acylaminotiazolderivat

Country Status (20)

Country	Link
US (2)	US5189049A (sv)
EP (1)	EP0432040B2 (sv)
JP (2)	JP2760903B2 (sv)
KR (1)	KR0147281B1 (sv)
AR (1)	AR248138A1 (sv)
AT (1)	ATE109145T1 (sv)
AU (1)	AU628696B2 (sv)
CA (1)	CA2031463C (sv)
DE (1)	DE69011059T3 (sv)
DK (1)	DK0432040T3 (sv)
ES (1)	ES2057490T5 (sv)
FI (1)	FI94249C (sv)
GR (1)	GR3025940T3 (sv)
HK (1)	HK1002030A1 (sv)
HU (2)	HU218276B (sv)
IE (1)	IE68593B1 (sv)
IL (1)	IL96577A (sv)
LV (1)	LV5802B4 (sv)
MX (1)	MX9203027A (sv)
NO (1)	NO179584C (sv)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2677356B1 (fr) *	1991-06-05	1995-03-17	Sanofi Sa	Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
US6558952B1 (en) *	1992-12-14	2003-05-06	Waratah Pharmaceuticals, Inc.	Treatment for diabetes
FR2701708B1 (fr) *	1993-02-19	1995-05-19	Sanofi Elf	Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
FR2703995B1 (fr) *	1993-04-16	1995-07-21	Sanofi Elf	5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant.
FR2714059B1 (fr) *	1993-12-21	1996-03-08	Sanofi Elf	Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
FR2754258B1 (fr)	1996-10-08	1998-12-31	Sanofi Sa	Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
CO4970713A1 (es) *	1997-09-19	2000-11-07	Sanofi Synthelabo	Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
FR2768737B1 (fr) *	1997-09-19	2000-05-19	Sanofi Sa	Derives de carboxamidothiazoles, leur preparation, les compositions pharmaceutiques en contenant
RO119463B1 (ro)	1997-10-27	2004-11-30	Agouron Pharmaceuticals, Inc.	Derivaţi de 4-aminotiazol şi utilizarea lor ca inhibitori ai cdk
FR2781227B1 (fr) *	1998-07-20	2002-02-22	Sanofi Sa	Procede pour la preparation du sel potassique du lintitript
US20040037818A1 (en) *	1998-07-30	2004-02-26	Brand Stephen J.	Treatment for diabetes
DE19908537A1 (de)	1999-02-26	2000-08-31	Aventis Pharma Gmbh	Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908538A1 (de)	1999-02-26	2000-08-31	Aventis Pharma Gmbh	Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
US6218408B1 (en)	1999-06-30	2001-04-17	Synaptic Pharmaceutical Corporation	Selective NPY (Y5) antagonists (bicyclics)
US6340683B1 (en)	1999-04-22	2002-01-22	Synaptic Pharmaceutical Corporation	Selective NPY (Y5) antagonists (triazines)
US6989379B1 (en)	1999-04-22	2006-01-24	H. Lundbick A/S	Selective NPY (Y5) antagonists
DE60034783T2 (de)	1999-04-22	2008-01-31	H. Lundbeck A/S, Valby	Selektive npy(y5)-antagonisten
US7273880B2 (en)	1999-06-30	2007-09-25	H. Lunbeck A/S	Selective NPY (Y5) antagonists
US6222040B1 (en)	1999-06-30	2001-04-24	Synaptic Pharmaceutical Corporation	Selective NPY (Y5) antagonists (tricyclics)
US6225330B1 (en)	1999-06-30	2001-05-01	Synaptic Pharmaceutical Corporation	Selective NPY (Y5) antagonists (tricyclics)
US6214853B1 (en)	1999-06-30	2001-04-10	Synaptic Pharmaceutical Corporation	Selective NPY (Y5) antagonists (bicyclics)
EP1254115A2 (en)	2000-02-11	2002-11-06	Bristol-Myers Squibb Company	Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
EP1305023A4 (en) *	2000-08-01	2005-02-23	Univ Virginia	USE OF ADENOSINE A1 RECEPTOR SELECTIVE ALLOSTERIC AGONISTS, ANTAGONISTS AND AMPLIFIERS TO MANIPULATE ANGIOGENESIS
US6992060B2 (en) *	2001-01-12	2006-01-31	Waratah Pharmaceuticals, Inc.	Prolonged efficacy of islet neogenesis therapy methods with a gastrin/CCK receptor ligand and an EGF receptor ligand composition in subjects with preexisting diabetes
JP4145654B2 (ja) *	2001-01-26	2008-09-03	塩野義製薬株式会社	トロンボポエチン受容体アゴニスト作用を有する環状化合物
EP1357116A4 (en) *	2001-02-02	2005-06-01	Yamanouchi Pharma Co Ltd	2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF
EP1314733A1 (en) *	2001-11-22	2003-05-28	Aventis Pharma Deutschland GmbH	Indole-2-carboxamides as factor Xa inhibitors
JP2005529846A (ja) *	2002-01-16	2005-10-06	ユニバーシティオブバージニアパテントファウンデーション	Ａ１アデノシン受容体の２−アミノチアゾールアロステリックエンハンサ
EP1466912B1 (en)	2002-01-18	2013-04-24	Astellas Pharma Inc.	2-acylaminothiazole derivative or salt thereof
US20050261298A1 (en) *	2002-01-18	2005-11-24	David Solow-Cordero	Methods of treating conditions associated with an Edg-7 receptor
EP1483283A4 (en)	2002-03-13	2007-04-11	Signum Biosciences Inc	MODULATION OF PROTEIN METHYLATION AND PHOSPHOPROTEIN PHOSPHATE
WO2003100024A2 (en) *	2002-05-24	2003-12-04	Waratah Pharmaceuticals, Inc.	Treatment for diabetes
EP1837031B1 (en) *	2002-06-07	2009-10-14	Waratah Pharmaceuticals, Inc.	Compositions and methods for treating diabetes
BR0312023A (pt)	2002-06-27	2005-03-22	Novo Nordisk As	Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
US20040229810A1 (en) *	2002-10-22	2004-11-18	Antonio Cruz	Gastrin compositions and formulations, and methods of use and preparation
US20080039379A1 (en) *	2003-05-27	2008-02-14	Waratah Pharmaceuticals, Inc.	Compositions Comprising Gastrin Compounds and Their Use in Diabetes
US7737133B2 (en) *	2003-09-03	2010-06-15	Agi Therapeutics Ltd.	Formulations and methods of treating inflammatory bowel disease
EP1532980A1 (en) *	2003-11-24	2005-05-25	Novo Nordisk A/S	N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
SI3002283T1 (en)	2003-12-26	2018-06-29	Kyowa Hakko Kirin Co., Ltd.	Thiazole derivatives
PL1723128T3 (pl)	2004-01-06	2013-04-30	Novo Nordisk As	Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy
MX2007001271A (es) *	2004-08-05	2007-03-21	Hoffmann La Roche	N-acil-2-aminotiazoles sustituidos.
SG155222A1 (en) *	2004-08-13	2009-09-30	Genentech Inc	Thiazole based inhibitors of atp-utilizing enzymes
WO2006080406A1 (ja) *	2005-01-28	2006-08-03	Taisho Pharmaceutical Co., Ltd.	三環性化合物
CA2601777A1 (en) *	2005-02-03	2006-08-10	Signum Biosciences, Inc.	Compositions and methods for enhancing cognitive function
US7923041B2 (en)	2005-02-03	2011-04-12	Signum Biosciences, Inc.	Compositions and methods for enhancing cognitive function
JPWO2006137527A1 (ja)	2005-06-23	2009-01-22	協和発酵キリン株式会社	チアゾール誘導体
WO2007006761A1 (en)	2005-07-08	2007-01-18	Novo Nordisk A/S	Dicycloalkylcarbamoyl ureas as glucokinase activators
JP4960355B2 (ja)	2005-07-14	2012-06-27	ノボ・ノルデイスク・エー／エス	ウレア型グルコキナーゼ活性化剤
KR20080074166A (ko) *	2005-11-08	2008-08-12	아스테라스 세이야쿠 가부시키가이샤	혈소판감소증을 치료하는 조성물 및 방법
TW200730476A (en) *	2005-12-12	2007-08-16	Genelabs Tech Inc	N-(5-membered aromatic ring)-amido anti-viral compounds
CN101096363B (zh) *	2006-06-27	2011-05-11	中国人民解放军军事医学科学院毒物药物研究所	2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途
ES2470333T3 (es) *	2006-08-08	2014-06-23	Akarx, Inc.	Composiciones y métodos para aumentar los niveles de plaquetas de la sangre en humanos
US8138185B2 (en)	2007-01-09	2012-03-20	Novo Nordisk A/S	Urea glucokinase activators
US8318778B2 (en)	2007-01-11	2012-11-27	Novo Nordisk A/S	Urea glucokinase activators
AU2009239430B2 (en)	2008-04-21	2015-01-22	Signum Biosciences, Inc.	Compounds, compositions and methods for making the same
EP2464352A1 (en) *	2009-08-14	2012-06-20	Eisai Inc.	Use of e5501 for stimulating platelet production
DE102011083271A1 (de) *	2011-09-23	2013-03-28	Beiersdorf Ag	Aromatische Amidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Aromatischen Amidothiazolen
MX367554B (es) *	2013-06-05	2019-08-27	C&C Res Lab	Derivados heterocíclicos y sus usos.
EP3016951B1 (en)	2013-07-02	2017-05-31	Bristol-Myers Squibb Company	Tricyclic pyrido-carboxamide derivatives as rock inhibitors
EP3016950B1 (en)	2013-07-02	2017-06-07	Bristol-Myers Squibb Company	Tricyclic pyrido-carboxamide derivatives as rock inhibitors
CN113321640B (zh) *	2017-06-22	2023-06-09	中国科学院广州生物医药与健康研究院	一种吲哚类化合物及其应用
EP4487909A3 (en)	2018-06-12	2025-03-19	vTv Therapeutics LLC	Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
WO2021167840A1 (en)	2020-02-18	2021-08-26	Vtv Therapeutics Llc	Sulfoxide and sulfone glucokinase activators and methods of use thereof
KR20230048502A (ko)	2020-06-08	2023-04-11	브이티브이 테라퓨틱스 엘엘씨	｛2-[3-사이클로헥실-3-(트랜스-4-프로폭시-사이클로헥실)-우레이도]-티아졸-5-일설파닐｝-아세트산의 염 또는 공결정 및 그의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2340092A2 (fr) *	1976-02-09	1977-09-02	Roussel Uclaf	Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
AT367871B (de) *	1980-05-16	1982-08-10	Hoerbiger Ventilwerke Ag	Anordnung zur selbsttaetigen druckentlastung von verdichtern
FR2482596A1 (fr) *	1980-05-19	1981-11-20	Roussel Uclaf	Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament
JPS5978171A (ja) *	1982-10-26	1984-05-04	Ikeda Mohandou:Kk	複素環式化合物
FR2566405B1 (fr) *	1984-06-25	1986-09-26	Roussel Uclaf	Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2 par une fonction aminee, leur preparation, leur application comme medicaments, les compositions les renfermant et les intermediaires nouveaux obtenus
DE3681358D1 (de) *	1985-07-09	1991-10-17	Pfizer	Substituierte oxindol-3-carboxamine als entzuendungshemmendes und schmerzstillendes mittel.
DE3705934A1 (de) *	1987-02-25	1988-09-08	Nattermann A & Cie	Indolyl-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4971978A (en) *	1987-09-21	1990-11-20	Nadzan Alex M	Derivatives of D-glutamic acid and D-aspartic acid
EP0348523A4 (en) *	1987-12-22	1991-10-09	Yoshitomi Pharmaceutical Industries, Ltd.	Thienodiazepine compounds and their medicinal use
GB8804448D0 (en) *	1988-02-25	1988-03-23	Smithkline Beckman Intercredit	Compounds
GB8820231D0 (en) *	1988-08-25	1988-09-28	Fujisawa Pharmaceutical Co	New benzazole compounds processes for preparation thereof & pharmaceutical composition comprising same
FR2701708B1 (fr) *	1993-02-19	1995-05-19	Sanofi Elf	Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
FR2703995B1 (fr) *	1993-04-16	1995-07-21	Sanofi Elf	5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant.

1990
- 1990-11-29 IE IE431090A patent/IE68593B1/en not_active IP Right Cessation
- 1990-12-03 FI FI905941A patent/FI94249C/sv not_active IP Right Cessation
- 1990-12-04 CA CA002031463A patent/CA2031463C/en not_active Expired - Fee Related
- 1990-12-05 DK DK90403458.4T patent/DK0432040T3/da active
- 1990-12-05 AT AT90403458T patent/ATE109145T1/de not_active IP Right Cessation
- 1990-12-05 AR AR90318535A patent/AR248138A1/es active
- 1990-12-05 HU HU075/90A patent/HU218276B/hu not_active IP Right Cessation
- 1990-12-05 US US07/622,620 patent/US5189049A/en not_active Ceased
- 1990-12-05 JP JP2406318A patent/JP2760903B2/ja not_active Expired - Lifetime
- 1990-12-05 EP EP90403458A patent/EP0432040B2/fr not_active Expired - Lifetime
- 1990-12-05 AU AU67779/90A patent/AU628696B2/en not_active Ceased
- 1990-12-05 ES ES90403458T patent/ES2057490T5/es not_active Expired - Lifetime
- 1990-12-05 NO NO905255A patent/NO179584C/no not_active IP Right Cessation
- 1990-12-05 DE DE69011059T patent/DE69011059T3/de not_active Expired - Fee Related
- 1990-12-06 KR KR1019900020116A patent/KR0147281B1/ko not_active Expired - Fee Related
- 1990-12-06 IL IL9657790A patent/IL96577A/en not_active IP Right Cessation
1992
- 1992-06-19 MX MX9203027A patent/MX9203027A/es unknown
1995
- 1995-06-29 HU HU95P/P00526P patent/HU211866A9/hu unknown
- 1995-09-11 US US08/526,079 patent/USRE37094E1/en not_active Expired - Lifetime
1996
- 1996-07-16 LV LV960248A patent/LV5802B4/xx unknown
1997
- 1997-08-06 JP JP9212074A patent/JP3035253B2/ja not_active Expired - Lifetime
1998
- 1998-01-16 GR GR980400110T patent/GR3025940T3/el unknown
- 1998-02-11 HK HK98101048A patent/HK1002030A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP3035253B2 (ja)	2000-04-24
IL96577A0 (en)	1991-09-16
DE69011059T2 (de)	1995-03-02
NO905255D0 (no)	1990-12-05
DE69011059D1 (de)	1994-09-01
KR0147281B1 (ko)	1998-08-17
HU908075D0 (en)	1991-06-28
ES2057490T3 (es)	1994-10-16
AU628696B2 (en)	1992-09-17
DK0432040T3 (da)	1994-10-31
AR248138A1 (es)	1995-06-30
US5189049A (en)	1993-02-23
EP0432040B1 (fr)	1994-07-27
FI905941A7 (sv)	1991-06-07
MX9203027A (es)	1992-07-01
IL96577A (en)	1994-06-24
HU211866A9 (en)	1995-12-28
JPH03279374A (ja)	1991-12-10
CA2031463C (en)	2000-07-25
LV5802A4 (lv)	1997-02-20
AU6777990A (en)	1991-06-20
CA2031463A1 (en)	1991-06-07
ES2057490T5 (es)	1998-03-16
HK1002030A1 (en)	1998-07-24
GR3025940T3 (en)	1998-04-30
EP0432040B2 (fr)	1997-12-17
FI94249B (sv)	1995-04-28
EP0432040A1 (fr)	1991-06-12
IE68593B1 (en)	1996-06-26
NO905255L (no)	1991-06-07
JPH10130147A (ja)	1998-05-19
NO179584C (no)	1996-11-06
KR910011814A (ko)	1991-08-07
NO179584B (no)	1996-07-29
USRE37094E1 (en)	2001-03-13
IE904310A1 (en)	1991-06-19
ATE109145T1 (de)	1994-08-15
DE69011059T3 (de)	1998-04-09
HU218276B (en)	2000-07-28
JP2760903B2 (ja)	1998-06-04
LV5802B4 (lv)	1997-08-20
HUT59400A (en)	1992-05-28
FI94249C (sv)	1995-08-10

Publication	Publication Date	Title
FI905941A0 (sv)	1990-12-03	Förfarande för framställning av terapeutiskt användbara heterocykliska 2-acylaminotiazolderivat
FI914905L (sv)	1992-04-19	Förfarande för framställning av nya terapeutiskt användbara merkaptoacetylamidopyrrolo- och -pyridobensazepinderivat
FI875660L (sv)	1987-12-22	Förfarande för framställning av terapeutiskt användbara 5-fenyl-2-pyrimidinonderivat
FI875024A7 (sv)	1988-05-15	Förfarande för framställning av terapeutiskt användbara 1-alkyl-6-halogentetrahydronaftalenderivat
FI925737A7 (sv)	1993-06-20	Förfarande för framställning av nya terapeutiskt användbara indol-3-ylalkylpiperazinderivat
FI96861C (sv)	1996-09-10	Förfarande för framställning av terapeutiskt aktiva substituerade indolylpyrrolderivat
FI883739A7 (sv)	1989-02-15	Förfarande för framställning av terapeutiskt aktiva fenoxiindanmetylaminderivat
FI892682L (sv)	1989-12-03	Analogiförfarande för framställning av terapeutiskt användbara 1-deoxinojirimycinderivat
FI900886A0 (sv)	1990-02-22	Förfarande för framställning av nya terapeutiskt användbara pyridinderivat
FI892787L (sv)	1989-12-11	Analogiförfarande för framställning av terapeutiskt användbara 1-indolylalkyl-4-(substituerat pyridinyl)piperaziner
FI881900A7 (sv)	1988-10-25	Analogiförfarande för framställning av terapeutiskt användbara substituerade imidazolylalkylpiperazin- och -diazepinderivat
FI923527L (sv)	1992-08-05	Förfarande för framställning av terapeutiskt användbara 3-piperidino-4-hydroxikromanderivat
FI874459A7 (sv)	1988-05-04	Förfarande för framställning av terapeutiskt användbara piperidinderivat
FI890072A7 (sv)	1989-07-09	Förfarande för framställning av farmaceutiskt användbara isokinolinderivat
FI891003A7 (sv)	1989-09-04	Förfarande för framställning av terapeutiskt användbara 6-substituerade purinylpiperazinderivat
FI930723A0 (sv)	1993-02-18	Förfarande för framställning av terapeutiskt aktiva tiazolidinderivat
FI896249A0 (sv)	1989-12-22	Förfarande för framställning av terapeutiskt användbara 7-oxabicykloheptylsubstituerade heterocykliska amidprostaglandinderivat
FI906408L (sv)	1991-06-29	Förfarande för framställning av terapeutiskt användbara 2-aminopyrimidin-4-karboxamidderivat
FI884553A7 (sv)	1989-04-06	Analogiförfarande för framställning av terapeutiskt användbara 9-aminotetrahydroakridinderivat
FI895393A0 (sv)	1989-11-13	Förfarande för framställning av terapeutiskt användbara alkylsubstituerade-2-alkylaminbensopyran-6-oler
FI894604L (sv)	1990-03-29	Förfarande för framställning av nya terapeutiskt användbara pyridyl- och pyrimidylpiperatzinderivat
FI883672A7 (sv)	1989-02-08	Förfarande för framställning av terapeutiskt användbara aminoalkoxifenylderivat
FI884910A0 (sv)	1988-10-24	Förfarande för framställning av terapeutiskt användbart bensopyranderivat
FI892946A7 (sv)	1989-12-16	Förfarande för framställning av nya terapeutiskt användbara 2,3,4,5-tetrahydro-1H-3-bensazepinderivat
FI893682L (sv)	1990-02-14	Förfarande för framställning av en terapeutiskt användbar 1,2,5-ditiazocinderivat

Legal Events

Date	Code	Title	Description
1995-04-03	BB	Publication of examined application
2004-08-31	MM	Patent lapsed	Owner name: SANOFI-SYNTHELABO